Sanofi SA
$
41.95
0 (0%)
On watch
| Volume: | 3,381,250 | Avg Vol (1m): | 1,504,745 |
| Market Cap $: | 103.83 Bil | Enterprise Value $: | 123.71 Bil |
| P/E (TTM): | 21.69 | P/B: | 1.60 |
| Earnings Power Value | 22.42 |
| Net Current Asset Value | -12.48 |
| Tangible Book | -3.24 |
| Projected FCF | 44.59 |
| Median P/S Value | 42.14 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 5.9/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.29 |
Cash-To-Debt range over the past 10 years
Min: 0.14, Med: 0.56, Max: 10.62
Current: 0.29
| |
| Equity-to-Asset | 0.53 |
Equity-to-Asset range over the past 10 years
Min: 0.48, Med: 0.58, Max: 0.65
Current: 0.53
| |
| Debt-to-Equity | 0.42 |
Debt-to-Equity range over the past 10 years
Min: 0.06, Med: 0.21, Max: 0.42
Current: 0.42
| |
| Debt-to-EBITDA | 2.70 |
Debt-to-EBITDA range over the past 10 years
Min: 0.7, Med: 1.49, Max: 2.7
Current: 2.7
| |
| Interest Coverage | 14.38 |
Interest Coverage range over the past 10 years
Min: 8.15, Med: 12.02, Max: 22.98
Current: 14.38
| |
| Piotroski F-Score | 6 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 1.59 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.50 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 11.94%
WACC 2.67%
| ||
Profitability & Growth : 7/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 17.53 |
Operating Margin range over the past 10 years
Min: 17.53, Med: 21.38, Max: 24.94
Current: 17.53
| |
| Net Margin % | 12.07 |
Net Margin range over the past 10 years
Min: 11.88, Med: 13.66, Max: 23.24
Current: 12.07
| |
| ROE % | 11.05 |
ROE range over the past 10 years
Min: 6.5, Med: 8.38, Max: 14.56
Current: 11.05
| |
| ROA % | 6.12 |
ROA range over the past 10 years
Min: 3.78, Med: 4.71, Max: 8.23
Current: 6.12
| |
| ROC (Joel Greenblatt) % | 71.62 |
ROC (Joel Greenblatt) range over the past 10 years
Min: 35.24, Med: 44.95, Max: 71.62
Current: 71.62
| |
| 3-Year Total Revenue Growth Rate | 0.80 |
3-Year Revenue Growth Rate range over the past 10 years
Min: -3.5, Med: 6, Max: 27.4
Current: 2.5
| |
| 3-Year Total EBITDA Growth Rate | -3.30 |
3-Year EBITDA Growth Rate range over the past 10 years
Min: -6.3, Med: 2, Max: 35.5
Current: -1.6
| |
| 3-Year EPS w/o NRI Growth Rate | 1.00 |
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -13.4, Med: 1, Max: 41.7
Current: 1
|
» SNY's 30-Y Financials
Financials (Next Earnings Date: 2019-10-31)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:SNY
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Drug Manufacturers » Drug Manufacturers NAICS : 325412 SIC : 2834 |
| Compare | NYSE:LLY NYSE:ABBV LSE:AZN NAS:AMGN LSE:GSK NAS:GILD NYSE:BMY NAS:CELG XTER:BAYA NAS:BIIB TSE:4519 TSE:4568 TSE:4503 XMAD:GRF.P TSE:4578 SHSE:600436 HKSE:01093 TSE:4528 TSE:4151 MIL:REC |
| Traded in other countries | SANO.Austria SAN.France SNW.Germany SANF.Italy SNYN.Mexico SAN.Switzerland 0O59.UK |
| Address | 54, Rue La Boétie, Paris, FRA, 75008 |
| Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just over 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent most of the remainder of sales. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 21.75 |
PE Ratio range over the past 10 years
Min: 9.55, Med: 19.98, Max: 32.04
Current: 21.75
| |
| Forward PE Ratio | 12.97 | N/A | |
| PE Ratio without NRI | 21.69 |
PE without NRI range over the past 10 years
Min: 11.06, Med: 21.42, Max: 32.66
Current: 21.69
| |
| Price-to-Owner-Earnings | 19.49 |
Price-to-Owner-Earnings range over the past 10 years
Min: 7.31, Med: 13.27, Max: 21.33
Current: 19.49
| |
| PB Ratio | 1.60 |
PB Ratio range over the past 10 years
Min: 1.16, Med: 1.61, Max: 2.33
Current: 1.6
| |
| PS Ratio | 2.63 |
PS Ratio range over the past 10 years
Min: 1.8, Med: 2.64, Max: 4.12
Current: 2.63
| |
| Price-to-Free-Cash-Flow | 26.25 |
Price-to-Free-Cash-Flow range over the past 10 years
Min: 7.49, Med: 15.49, Max: 27.97
Current: 26.25
| |
| Price-to-Operating-Cash-Flow | 16.89 |
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 6.08, Med: 11.61, Max: 18
Current: 16.89
| |
| EV-to-EBIT | 22.97 |
EV-to-EBIT range over the past 10 years
Min: 9.6, Med: 16.7, Max: 24.6
Current: 22.97
| |
| EV-to-EBITDA | 12.18 |
EV-to-EBITDA range over the past 10 years
Min: 5.1, Med: 9.9, Max: 14.6
Current: 12.18
| |
| EV-to-Revenue | 3.10 |
EV-to-Revenue range over the past 10 years
Min: 1.9, Med: 2.9, Max: 4.4
Current: 3.1
| |
| Shiller PE Ratio | 17.69 |
Shiller PE Ratio range over the past 10 years
Min: 14.6, Med: 19.2, Max: 27.44
Current: 17.69
| |
| Current Ratio | 1.42 |
Current Ratio range over the past 10 years
Min: 0.79, Med: 1.72, Max: 2.71
Current: 1.42
| |
| Quick Ratio | 0.99 |
Quick Ratio range over the past 10 years
Min: 0.59, Med: 1.27, Max: 2.41
Current: 0.99
| |
| Days Inventory | 152.10 |
Days Inventory range over the past 10 years
Min: 152.1, Med: 217.06, Max: 230.38
Current: 152.1
| |
| Days Sales Outstanding | 74.27 |
Days Sales Outstanding range over the past 10 years
Min: 69.78, Med: 76.56, Max: 83.73
Current: 74.27
| |
| Days Payable | 160.91 |
Days Payable range over the past 10 years
Min: 104.92, Med: 125.26, Max: 160.91
Current: 160.91
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| Dividend Yield % | 4.17 |
Trailing Dividend Yield range over the past 10 years
Min: 2.83, Med: 3.96, Max: 5.24
Current: 4.17
| |
| Dividend Payout Ratio | 1.09 |
Dividend Payout Ratio range over the past 10 years
Min: 0.55, Med: 0.86, Max: 1.09
Current: 1.09
| |
| 3-Year Dividend Growth Rate (Per Share) | 2.10 |
3-Year Dividend Growth Rate range over the past 10 years
Min: -15.6, Med: 6.5, Max: 37.9
Current: 2.1
| |
| Forward Dividend Yield % | 4.15 | N/A | |
| Yield-on-Cost (5-Year) % | 4.58 |
Yield-on-Cost (5y) range over the past 10 years
Min: 3.11, Med: 4.35, Max: 5.76
Current: 4.58
| |
| 3-Year Share Buyback Rate | 1.30 |
3-Year Share Buyback Rate range over the past 10 years
Min: -24.5, Med: 0.5, Max: 2.2
Current: 1.3
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 0.94 |
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.58, Med: 0.93, Max: 1.45
Current: 0.94
| |
| Price-to-Median-PS-Value | 1.00 |
Price-to-Median-PS-Value range over the past 10 years
Min: 0.7, Med: 1.13, Max: 3.58
Current: 1
| |
| Earnings Yield (Joel Greenblatt) % | 4.37 |
Earnings Yield (Greenblatt) range over the past 10 years
Min: 4.1, Med: 6, Max: 10.5
Current: 4.37
| |
| Forward Rate of Return (Yacktman) % | 5.62 |
Forward Rate of Return range over the past 10 years
Min: 1, Med: 6.05, Max: 19.2
Current: 5.62
|
More Statistics
| Revenue (TTM) (Mil) $ | 41,095.81 |
| EPS (TTM) $ | 1.97 |
| Beta | 0.45 |
| Volatility % | 15.44 |
| 52-Week Range $ | 40.19 - 45.62 |
| Shares Outstanding (Mil) | 2,490.91 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 6 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | N |
| CFROA > ROA | Y |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | Y |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | Y |